00:00It's Benzinga, bringing Wall Street to Main Street.
00:02Merck reported first quarter results that beat estimates,
00:06driven by strong demand for its cancer immunotherapy drug,
00:10Keytruda, and newer products.
00:12The pharmaceutical giant reported first quarter
00:15adjusted loss of $1.28 per share on $16.29 billion in revenue,
00:22beating Wall Street estimates of a $1.51 loss per share
00:26and $15.82 billion in revenue.
00:29Revenue rose 5% year over year.
00:32The company posted a net loss of $4.24 billion
00:35due to a $3.62 per share charge
00:38tied to its Sedera Therapeutics acquisition.
00:42Keytruda sales reached $8.03 billion,
00:45topping estimates and rising 12% on demand
00:48for earlier stage and metastatic cancer treatment.
00:52WinRiver generated $525 million in sales,
00:55exceeding expectations.
00:57Gardasil sales fell 19% to $1.07 billion
01:01amid weak demand in China, Japan, and the U.S.
01:05Merck narrowed its 2026 revenue outlook
01:08to $65.8 billion to $67 billion
01:11and raised adjusted earnings guidance
01:14to 5.04 to 5.16 per share.
01:16For all things money, visit Benzinga.com.
Comments